Receptor-mediated tumor targeting based on peptide hormones

Expert Opinion on Drug Delivery

Volumn 7, Issue 1, 2010, Pages 79-96

  Mezo, Gábor ^a   Manea, Marilena ^b  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Cancer diagnosis and therapy; Drug delivery systems; Gonadotropin releasing hormone; Receptor mediated tumor targeting; Somatostatin

Indexed keywords

2 PYRROLINODOXORUBICIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ISOTOPE LABELING; NEUTRON CAPTURE THERAPY; NONHUMAN; REVIEW;

CELL LINE, TUMOR; HORMONES; HUMANS; NEOPLASMS; PEPTIDES; RECEPTORS, LHRH;

EID: 73649137902     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903418410     Document Type: Review

References (99)

1. World Health Organization (WHO). Available from: http://www.who.int/ cancer/en/, Fact sheet Nr. 297, February 2009
2. Frei E III, Antman KH. Combination chemotherapy, dose, and schedule. In: Holland JR, Bast RC Jr, Morton DL, Frei E III, Kufe DW, Weichselbaum RR, editors, Cancer medicine. 4th Edition. Baltimore: Williams and Wilkins; 1997. p. 817-837
3. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300-310
4. Magrath T. Targeted approaches to cancer therapy. Int J Cancer 1994;56:163-166
5. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427
6. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14
7. Moody TW, Mantey SA, Pradhan TK, et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem 2004;279:23580-23589
8. Moody TW, Sun L-CH, Mantey SA. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharm Exp Ther 2006;318:1265-1272
9. Okarvi SM. Peptide based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 2008;34:13-26
10. Ulbrich K, Etrych T, Chytil P, et al. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release 2003;87:33-47
11. Shiose Y, Ochi Y, Kuga H, et al. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity ins tumors. Biol Pharm Bull 2007;30:2365-2370
12. Neill JD, Musgrove LC, Duck LW. Newly recognized GnRH receptors: function and relative role. Trends Endocrinol Metab 2004;15:383-392
13. Shedgley KR, Finch AR, Caunt CJ, McArdle CA. Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells. J Endocrinol 2006;191:625-636
14. Millar RP, Lowe WN, Conklin D, et al. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 2001;98:9636-9641
15. Neill JD, Duck LW, Sellers JC, Musgrove LC. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH-II in primates. Biochem Biophys Res Commun 2001;282:1012-1018
16. Caunt CJ, Finch AR, Sedgley KR, et al. Arrestin-mediated ERK activation by gonadotropin-releasing hormone receptors: receptor-specific activation mechanisms and compartmentalization. J Biol Chem 2006;281:2701-2710
17. Gründker C, Günthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002;87:1427-1430
18. Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Endocrinol Metab 2007;3:157-167
19. Gründker C, Schlotawa L, Viereck V, et al. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004;151:141-149
20. Fister S, Günthert AR, Emons G, Gründker C. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007;67:1750-1756
21. Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005;73:851-859 (Pubitemid 41507486)
22. Keller G, Schally AV, Gaiser T, et al. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Res 2005;65:5857-5863 (Pubitemid 40911191)
23. Keller G, Schally AV, Gaiser T, et al. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with cytotoxic LHRH analogue AN-207. Eur J Cancer 2005;41:2196-2202 (Pubitemid 41337963)
24. Nagy A, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): a new approach to targeted chemotherapy. Drugs Future 2002;27:359-370
25. Mezo G, Manea M, Szabó I, et al. New derivatives of GnRH as potential anticancer therapeutic agents. Curr Med Chem 2008;15:2366-2379
26. Nagy A, Schally AV, Armatis P, et al. Cytotoxic analog luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-7273
27. Chatzistamou I, Schally AV, Nagy A, et al. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clin Cancer Res 2000;6:4158-4165
28. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008;40:315-322
29. Kovács M, Szepesházi K, Schally AV. Endocrine and antineoplastic effects of antagonistic and cytotoxic analogs of luteinising hormone-releasing hormone. In: Kovács M, Merchenhalter I, editors, Neuropeptides and peptide analogs. Research Signpost, Kerela, India; 2009. p. 33-57
30. Keller G, Schally AV, Gaiser T, et al. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res 2005;11:5549-5557 (Pubitemid 41060832)
31. Szepesházi K, Schally AV, Halmos G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 2007;30:1485-1492
32. Szepesházi K, Schally AV, Treszl A, et al. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anticancer Drugs 2008;19:349-358
33. Günther, A, Gründker C, et al. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 2004;191:1164-1172 (Pubitemid 39421567)
34. Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinol 2009;90:15-18
35. Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin-14-O- hemiglutarate in mouse and human serum in vitro: implications for the preclinical studies. Proc Natl Acad Sci USA 2000;97:829-834
36. Kovács M, Schally AV, Nagy A, et al. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997;94:1420-1425
37. Schally AV, Halmos G, Rékasi Z, Arencibia-Jimenez JM. The actions of LH-RH agonists and antagonists and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors. In: P Devroey, editor, Infertility and reproductive medicine clinica of North America. Philadelphia: Saunders. 2001;12:17-44
38. Sower SA, Chiang Y-C, Lovas S, Conlon JM. Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. Endocrinol 1993;132:1125-1131
39. Lovas S, Pályi I, Vincze B, et al. Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res 1998;52:384-389
40. Kovács M, Seprodi J, Koppán M, et al. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol 2002;14:1-14
41. Szabó I, Manea M, Orbán E, et al. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 2009;20:656-665
42. Kovács M, Vincze B, Horváth JE, Seprodi J. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs. Peptides 2007;28:821-829
43. Sibrian-Vazquez M, Jensen TJ, Vicente MG. Synthesis, characterization, and metabolic stability of porphyrin-peptide conjugates bearing bifunctional signaling sequences J Med Chem 2008;51:2915-2923
44. Bai KB, Láng O, Orbán E, et al. Design, synthesis, and in vitro activity of novel drug delivery systems containing tuftsin derivatives and methotrexate. Bioconjug Chem 2008;19:2260-2269
45. Rahimipour S, Ben-Aroya N, Ziv K, et al. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J Med Chem 2003;46:3965-3974
46. Dharap SS, Qui B, Williams GC, et al. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 2003;91:61-73
47. Dharap SS, Wang Y, Chandna P, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA 2005;102:12962-12967
48. Khandare JJ, Chandna P, Wang Y, et al. Novel polymeric prodrug with multivalent components for cancer therapy. J Pharm Exp Ther 2006;317:929-937
49. Chandna P, Saad M, Wang Y, et al. Targeted proapoptotic anticancer drug delivery system. Mol Pharm 2007;4:668-678
50. Dharap SS, Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 2003;20:889-896
51. Barda Y, Cohen N, Lev V, et al. Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl Med Biol 2004;31:921-933
52. Schottelius M, Berger S, Poethko T, et al. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRH-targeting efficiency. Bioconjug Chem 2008;19:1256-1268
53. Pawson AJ, Faccenda E, Maudsley S, et al. Mammalian type I Gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization. Endocrinology 2008;149:1415-1422
54. Montagnani-Marelli M, Moretti RM, Januszkiewicz-Caulier J, et al. Gonadotropin-releasing hormone (GnRH) receptor sin tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 2006;6:257-269
55. Bauer W, Briner U, Doepfner W, et al. SMS-201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-1140
56. Cai R-Z, Szoke B, Lu R, et al. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 1986;83:1896-1900
57. Nagy A, Schally AV, Halmos G, et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1998;95:1794-1799
58. Schally AV, Comaru-Schally M, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-291
59. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-2320
60. Engel JB, Schally AV, Halmos G, et al. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-I. Cancer 2005;104:1312-1321
61. O'Byrne KJ, Schally AV, Thomas A, et al. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy 2001;47(S):78-108
62. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancerwith 99mTc depreotide. Semin Nucl Med 2002;32:92-96
63. Kiaris H, Schally AV, Nagy A, et al. A targeted cytotoxic somatostatin (SST) analog, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer 2001;37:620-628
64. Szereday Z, Schally AV, Szepesházi K, et al. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 2003;22:1141-1146
65. Treszl A, Schally AV, Seitz S, et al. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides 2009;30:1643-1650
66. Seitz S, Schally AV, Treszl A, et al. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. Anticancer Drugs 2009;20:553-558
67. Huang C-M, Wu Y-T, Chen S-T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem Biol 2000;7:453-461
68. Nicolau KC, Dai WM, Guy RK. Chemistry and biology of taxol. Angew Chem Int Ed Engl 1994;33:15-44
69. Sun ML, Wei JM, Wang XW, et al. Paclitaxel-octreotide conjugates inhibit growth of human non-small lung cancer cells in vitro. Exp Oncol 2007;29:186-191
70. Shen H, Hu D, Du J, et al. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur J Pharmacol 2008;601:23-29
71. Fuselier JA, Sun L, Woltering SN, et al. An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett 2003;13:799-803
72. Patterson LH, McKeowen SR, Robson T, et al. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 1999;14:473-486
73. Cha SW, Gu HK, Lee KP, et al. Immunotoxicity of ethyl carbamate in female BALB/c mice: role of esterase and cytochrome P450. Toxicology Lett 2000;115:173-181
74. Moody TW, Fuselier J, Coy DH, et al. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides 2005;26:1560-1566
75. Sun L-C, Fuselier JA, Coy DH. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumor sin rodents. Drug Deliv 2004;11:231-238
76. Bezerra Y, Fuselier JA, Peyma GA, et al. Study of inhibition effects o fan antiangiogenic somatostatin camtothecin conjugate on laser-induced choroidal neovascularization in rats. Retina 2005;25:345-354
77. Sun L-C, Luo J, Mackey LV, et al. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 2007;246:157-166
78. John A, Tuszynszki G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23
79. Mier W, Gabel D, Haberkorn U, Eisenhut M. Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumour selective peptide. Z Anorg Chem 2004;630:1258-1262
80. Betzel T, Hess T, Waser B, et al. closo-Borane conjugated regulatory peptides retain high biological affinity: Synthesis of closo-borane conjugated Tyr3-octreotate derivatives for BNCT. Bioconjug Chem 2008;19:1796-1802
81. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-441
82. Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111In-DTPA-D-Phe1- octreotide in 194 carcinoid patients: Vienna university experience, 1993-1998. J Clin Oncol 2000;18:1331-1336
83. Rufini V, Calcagini ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-247
84. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-1713
85. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOCin association with amino acid infusion; a phase 1 study. Eur J Nucl Med 2003;30:207-216
86. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282
87. Henze M, Schumacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68Ga] DOTA-D-Phe1-Tyr3-octreotid: first results in patients with meningiomas. J Nucl Med 2001;42:1053-1056
88. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patientswith metastatic neuroendocrine tumors scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460-466
89. Storch D, Béhé M, Walter MA, et al. Evaluation of [99mTc/EDDA/HYNIC0] octreotide derivatives compared with [111In-DOTA0,Tyr3,Thr8] octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561-1569
90. Gambini JP, López Lerena JJ, Quagliata A, et al. 99mTc-HYNIC octreotide in neuroblastoma. Ann Nucl Med 2008;22:817-819
91. Chen L, Li F, Zhuang H, et al. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med 2009;50:397-400
92. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46S:62-66
93. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-140
94. Mier W, Graham KAN, Wang Q, et al. Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. Tetrahedron Lett 2004;45:5453-5455
95. Nayak TK, Atcher RW, Prossnitz ER, Norenberg JP. Enhancement of somatostatin-receptor-targeted 177Lu-[DOTA0-Tyr3]-octreotide therapy by gemcitabine prtreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol 2008;35:673-678
96. Nayak TK, Norenberg JP, Anderson TL, et al. Somatostatin-receptor- targeted a-emitting 213Bi is therapeutically more effective than betā-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 2007;34:185-193
97. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006;103:16436-16441
98. Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006;47:502-511
99. Cescato R, Erchegyi J, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 2008;51:4030-4037